Retrospective 266 COVID-19 ICU patients in India, showing significantly lower mortality with PVP-I oral gargling and topical nasal use, and non-statistically significant higher mortality with ivermectin and lower mortality with remdesivir.
risk of death, 53.0% higher, RR 1.53, p = 0.13, treatment 32 of 76 (42.1%), control 69 of 190 (36.3%), adjusted per study, multivariable Cox regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jamir et al., 13 Dec 2021, retrospective, India, peer-reviewed, 6 authors, study period June 2020 - October 2010, dosage not specified.